With the continuous deepening of the concept of precision diagnosis and treatment for lung cancer, how to achieve higher efficiency and accuracy in the screening, diagnosis, and treatment pathways in clinical practice has become an important issue that urgently needs to be overcome. The current clinical difficulty lies in the fact that despite continuous advancements in imaging and molecular diagnostic technologies, there are still limitations in manual efficiency and subjective experience when it comes to massive data analysis and multi-scale feature extraction. Artificial intelligence (AI), especially algorithm systems based on deep learning, is an innovative technology capable of deeply empowering medical big data. This method utilizes algorithms such as convolutional neural networks, combined with radiomics, pathomics, and multi-modal data fusion analysis, demonstrating immense potential in early precise detection and benign-malignant differentiation of pulmonary nodules, digital pathological subtype recognition and non-invasive prediction of driver genes, precise 3D surgical planning and automatic delineation of radiotherapy target volumes, as well as dynamic risk warning during follow-up. This innovative technology provides a brand-new solution for realizing intelligent and individualized lung cancer diagnosis and treatment models. This consensus, based on the latest evidence from evidence-based medicine and combined with the development trends in the AI field and real-world clinical needs, was ultimately formed by gathering the consensus opinions of multidisciplinary experts in radiology, pathology, thoracic surgery, and other fields. The main content covers the application specifications of AI in the three core scenarios of lung cancer screening, diagnosis, and treatment, the technical standards for data collection and algorithm validation, as well as the ethical and regulatory challenges faced at the current stage. It aims to clarify the applicable boundaries of AI as a clinical auxiliary decision support tool, providing scientific guidance and standardized exploration directions for peers currently engaged in or planning to carry out AI-assisted clinical diagnosis, treatment, and translation of lung cancer.

Patients with lung cancer experience a heavy symptom burden during the perioperative period, which seriously affects their recovery and quality of life. Traditional symptom management models rely mainly on scheduled ward rounds during hospitalization and outpatient follow-up after discharge. However, they have limitations such as delayed symptom recognition, lack of post-discharge monitoring, and non-quantitative symptom assessment, which often lead to delayed interventions and low patient satisfaction. In recent years, the symptom management model based on electronic patient-reported outcomes (ePRO) has been increasingly valued in clinical practice. Existing high-level evidence from both domestic and international studies indicates that, through proactive monitoring, real-time alerts, and remote interventions, this model enables dynamic and continuous symptom management and helps improve patient recovery and healthcare experience. As a supplement to routine medical care, the ePRO-based symptom management model aims to enhance the quality of care rather than replace existing medical processes. To promote the standardized application of this model in perioperative lung cancer care, this consensus integrates domestic and international evidence. After multiple rounds of voting by more than 50 experts, it formulates 12 consensus statements covering the three core components, symptom monitoring, alerting, and intervention, to provide scientific and practical recommendations for clinical practice.

Objective We reviewed and analyzed the epidemiological data of 83 imported dengue fever cases reported in Fengtai District, Beijing, from 2007 to 2025, to delineate their epidemiological characteristics and guide the dengue fever prevention and control strategy in the future. Methods Data on dengue fever cases in Fengtai District from 2007 to 2025 were collected to identify the epidemic factors and characteristics using descriptive epidemiological method. Results All 83 dengue fever cases reported in this region over the past two decades have been imported from abroad or other domestic areas, with Southeast Asian countries being identified as the primary source of imported infections, accounting for 42 cases (50.60%), followed by 15 cases (18.07%) from Chinese provinces other than Beijing. The remaining import sources included 13 cases from South Asia,8 from African countries, and each from Oceania, South America, and Europe. Disease onset was found concentrated between May and November. The sex ratio (male-to-female) is 1.59:1. The age of onset ranged from 14 to 61 years old, with a median age of 36. The largest proportion of cases was observed among cadres and office workers (31 cases, 37.35%), followed by businessmen (13 cases, 15.67%), and householders or the unemployed (10 cases,12.05%). Travel visit was identified as the primary reason for their exposure history. Conclusions All dengue fever cases reported in Fengtai from 2007 to 2025 were imported, with an increasing trend of imported cases in Beijing originating from other Chinese provinces. It is essential to strengthen health education for foreign travelers and returning residents, enhance clinical diagnosis and treatment training for medical personnel, eliminate mosquito breeding sites, and reduce mosquito density through active patriotic health campaigns.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated death globally. Liver transplantation (LT) has emerged as a key treatment for patients with HCC, and the Milan criteria have been adopted as the cornerstone of the selection policy. To allow more patients to benefit from LT, a number of expanded criteria have been proposed, many of which use radiologic morphological characteristics with larger and more tumors as surrogates to predict outcomes. Other groups developed indices incorporating biological variables and dynamic markers of response to locoregional treatment. These expanded selection criteria achieved satisfactory results with limited liver supplies. In addition, a number of prognostic models have been developed using clinicopathological characteristics, imaging radiomics features, genetic data, and advanced techniques such as artificial intelligence. These models could improve prognostic estimation, establish surveillance strategies, and bolster long-term outcomes in patients with HCC. In this study, we reviewed the latest findings and achievements regarding the selection criteria and post-transplant prognostic models for LT in patients with HCC.

Objective:To investigate the expression of peptide transporter 1 (PEPT1) in gastric cancer and its clinical significance.Methods:PEPT1 protein expression and localization in human gastric cancer BGC-823, SGC-7901, MKN-45 cells were evaluated using cellular immunofluorescence staining. The expression of PEPT1 protein and mRNA in normal mucosal epithelial GES-1 cells, BGC-823, SGC-7901 and MKN-45 cells was detected by Western blot and quantitative real-time PCR (qPCR). Bioinformatics was used to analyze the expression of the slc15a1 gene, which encodes PEPT1, in gastric cancer and adjacent normal tissues. The PEPT1 expression in different pathological types of gastric cancer and adjacent normal tissues was detected by immunohistochemical staining. The serum samples of peripheral blood from 18 gastric cancer patients admitted to the Tianjin Medical University General Hospital from June to December 2019 were collected for the gastric cancer group, and the serum samples of peripheral blood from 21 gastric polyps patients were collected for the gastric polyp group. The expression level of PEPT1 in the two groups′ serum samples was detected by enzyme-linked immunosorbent assay. The diagnostic efficacy of PEPT1 was evaluated using a receiver operator characteristic curve method. The correlation between PEPT1 and gastric cancer markers was evaluated by the Pearson correlation analysis. The slc15a1 RNA interference lentivirus was constructed and transfected into MKN-45 cells, which were divided into a CON313 negative control group and a knockdown group. The effect of slc15a1 gene knockdown on MKN-45 cells proliferation was detected using cell counting kit-8 (CCK-8), Western blotting and qPCR assays. The slc15a1 RNA overexpression lentivirus was constructed and transfected into colon cancer Caco-2 cells, which were divided into a CON335 negative control group and an overexpression group. The effect of overexpression of slc15a1 gene on Caco-2 cells proliferation was detected using CCK-8, Western blotting, qPCR, and cell clone formation assays. Results:Different intensities of red fluorescence representing the PEPT1 protein were observed on the membranes of BGC-823, SGC-7901, and MKN-45 cells. PEPT1 protein expression was higher in BGC-823 (0.603±0.030), SGC-7901 (0.743±0.029), MKN-45 (0.835±0.029) cells than that in GES-1 cells (0.486±0.020) ( P<0.05, 0.01). The relative PEPT1 mRNA expression level in SGC-7901 cells (22.540±0.150) was higher than that in GES-1 cells (18.530±0.137) ( P<0.01). However, the relative PEPT1 mRNA expression level in BGC-823 (17.800±0.057) and MKN-45 (8.050±0.053) cells was lower than that in GES-1 cells (both P<0.01). Slc15a1 expression in gastric cancer tissues was significantly higher than that in adjacent normal gastric tissues ( P<0.05). PEPT1 was expressed in papillary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma and squamous cell carcinoma, and the expression level was higher than that in adjacent normal gastric tissues. The PEPT1 expression in serum samples of gastric cancer patients [(3.002 8±0.689 4) ng/ml] was higher than that in gastric polyps patients [(2.575 7±0.468 1) ng/ml] ( P<0.05). The detection sensitivity and specificity of PEPT1 were 0.714 and 0.684, respectively, and the area under the curve was 0.659. A significant positive correlation was observed between PEPT1 and carcinoembryonic antigen ( R=0.459, P<0.05). The relative expression level of PEPT1 mRNA in the knockdown group (0.484±0.003) was significantly lower than that in the CON313 negative control group (1.000±0.029) ( P<0.01). There was no significant difference in the relative expression of PEPT1 protein between the knockdown group (0.954±0.007) and the CON313 negative control group (0.949±0.020) ( P>0.05). As culture time increased, the absorbance ( A) values in the knockdown group at 24, 48, 72, 96, and 120 h (0.227±0.001, 0.642±0.007, 0.773±0.006, 0.938±0.038, 1.263±0.017) were gradually decreased from 48 h compared with those in the CON313 negative control group (0.217±0.006, 0.644±0.001, 0.802±0.020, 1.053±0.002, 1.507±0.002), and the A values of the knockdown group at 96 and 120 h were significantly lower than those of the CON313 negative control group (both P<0.01). The relative expression level of PEPT1 mRNA in the overexpression group (6.696±0.071) was significantly higher than that in the CON335 negative control group (1.001±0.048) ( P<0.01). However, there was no significant difference in the relative expression of PEPT1 protein between the overexpression group (0.899±0.007) and the CON335 negative control group (0.808±0.011) ( P>0.05). As culture time increased, the A values of the overexpression group at 24, 48, 72, 96, and 120 h (0.212±0.009, 0.347±0.005, 0.639±0.003, 1.092±0.007, 1.39±0.010) were gradually increased compared with those in the CON335 negative control group (0.199±0.002, 0.323±0.003, 0.483±0.003, 0.787±0.007, 0.926±0.003) (all P<0.05). The results of cell clone formation assay showed that the number of clonal cells in the overexpression group [(371±8) cells] was significantly higher than that in the CON335 negative control group [(227±7) cells] ( P<0.05). Conclusions:PEPT1 is specifically overexpressed in gastric cancer. It affects the proliferation of gastric cancer cells by regulating slc15a1 gene expression. As a tumor marker, PEPT1 has a certain potential value in the clinical diagnosis and treatment of gastric cancer.

BACKGROUND:The phosphatidylinositol 3-kinase/protein kinase(PI3K/AKT)signaling pathway plays a pivotal role in regulating osteoclast activation,which is essential for maintaining bone homeostasis.Bone destruction in osteoarticular tuberculosis is caused by aberrant osteoclastogenesis induced by Mycobacterium tuberculosis infection.However,the role of the PI3K signaling pathway in Mycobacterium tuberculosis-induced aberrant osteoclastogenesis remains unclear. OBJECTIVE:To investigate the effects and mechanisms of the PI3K/AKT signaling pathway inhibitor BYL-719 on aberrant osteoclastogenesis induced by Mycobacterium tuberculosis. METHODS:RAW264.7 cells were infected with bovine Mycobacterium tuberculosis bacillus calmette-cuerin vaccine,and Ag85B was used for cellular immunofluorescence staining.The cell counting kit-8 assay was employed to determine the safe concentration of BYL-719.There were four groups in the experiment:blank control group,BYL-719 group,BCG group,and BCG+BYL-719 group.Under the induction of receptor activator of nuclear factor kappa-B ligand,the effects of BYL-719 on post-infection osteoclast differentiation and fusion were explored through tartrate-resistant acid phosphatase staining and phalloidin staining.RT-PCR and western blot were used to detect the expression of osteoclast-related genes and proteins,and further investigate the mechanism of action. RESULTS AND CONCLUSION:Immunofluorescence staining showed that RAW264.7 cells phagocytosed Mycobacterium tuberculosis.Cell counting kit-8 data indicated that 40 nmol/L BYL-719 was non-toxic to cells.Tartrate-resistant acid phosphatase staining and phalloidin staining showed that BYL-719 inhibited the generation and fusion ability of osteoclasts following infection.RT-PCR and western blot results also indicated that BYL-719 suppressed the upregulation of osteoclast-specific genes(including c-Fos,NFATc1,matrix metalloproteinase 9,and CtsK)induced by Mycobacterium tuberculosis infection(P<0.05).Western blot and immunofluorescence staining revealed that BYL-719 inhibited excessive osteoclast differentiation induced by Mycobacterium tuberculosis by downregulating the expression of IκBα-p65.To conclude,BYL-719 inhibits aberrant osteoclastogenesis induced by Mycobacterium tuberculosis through the downregulation of IκBα/p65.Therefore,the IκBα/p65 signaling pathway is a potential therapeutic target for osteoarticular tuberculosis,and BYL-719 holds potential value for the preventing and amelioration of bone destruction in osteoarticular tuberculosis.BYL-719 has the potential to prevent and ameliorate bone destruction in osteoarticular tuberculosis.

Purpose: The aim of this study was to investigate the feasibility of an intelligent handheld ultrasound (US) device for assisting non-expert general practitioners (GPs) in detecting carotid plaques (CPs) in community populations. Methods: This prospective parallel controlled trial recruited 111 consecutive community residents. All of them underwent examinations by non-expert GPs and specialist doctors using handheld US devices (setting A, setting B, and setting C). The results of setting C with specialist doctors were considered the gold standard. Carotid intima-media thickness (CIMT) and the features of CPs were measured and recorded. The diagnostic performance of GPs in distinguishing CPs was evaluated using a receiver operating characteristic curve. Inter-observer agreement was compared using the intragroup correlation coefficient (ICC). Questionnaires were completed to evaluate clinical benefits. Results: Among the 111 community residents, 80, 96, and 112 CPs were detected in settings A, B, and C, respectively. Setting B exhibited better diagnostic performance than setting A for detecting CPs (area under the curve, 0.856 vs. 0.749; P<0.01). Setting B had better consistency with setting C than setting A in CIMT measurement and the assessment of CPs (ICC, 0.731 to 0.923). Moreover, measurements in setting B required less time than the other two settings (44.59 seconds vs. 108.87 seconds vs. 126.13 seconds, both P<0.01). Conclusion Using an intelligent handheld US device, GPs can perform CP screening and achieve a diagnostic capability comparable to that of specialist doctors.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated death globally. Liver transplantation (LT) has emerged as a key treatment for patients with HCC, and the Milan criteria have been adopted as the cornerstone of the selection policy. To allow more patients to benefit from LT, a number of expanded criteria have been proposed, many of which use radiologic morphological characteristics with larger and more tumors as surrogates to predict outcomes. Other groups developed indices incorporating biological variables and dynamic markers of response to locoregional treatment. These expanded selection criteria achieved satisfactory results with limited liver supplies. In addition, a number of prognostic models have been developed using clinicopathological characteristics, imaging radiomics features, genetic data, and advanced techniques such as artificial intelligence. These models could improve prognostic estimation, establish surveillance strategies, and bolster long-term outcomes in patients with HCC. In this study, we reviewed the latest findings and achievements regarding the selection criteria and post-transplant prognostic models for LT in patients with HCC.

Purpose: The aim of this study was to investigate the feasibility of an intelligent handheld ultrasound (US) device for assisting non-expert general practitioners (GPs) in detecting carotid plaques (CPs) in community populations. Methods: This prospective parallel controlled trial recruited 111 consecutive community residents. All of them underwent examinations by non-expert GPs and specialist doctors using handheld US devices (setting A, setting B, and setting C). The results of setting C with specialist doctors were considered the gold standard. Carotid intima-media thickness (CIMT) and the features of CPs were measured and recorded. The diagnostic performance of GPs in distinguishing CPs was evaluated using a receiver operating characteristic curve. Inter-observer agreement was compared using the intragroup correlation coefficient (ICC). Questionnaires were completed to evaluate clinical benefits. Results: Among the 111 community residents, 80, 96, and 112 CPs were detected in settings A, B, and C, respectively. Setting B exhibited better diagnostic performance than setting A for detecting CPs (area under the curve, 0.856 vs. 0.749; P<0.01). Setting B had better consistency with setting C than setting A in CIMT measurement and the assessment of CPs (ICC, 0.731 to 0.923). Moreover, measurements in setting B required less time than the other two settings (44.59 seconds vs. 108.87 seconds vs. 126.13 seconds, both P<0.01). Conclusion Using an intelligent handheld US device, GPs can perform CP screening and achieve a diagnostic capability comparable to that of specialist doctors.

Apical microsurgery is accurate and minimally invasive, produces few complications, and has a success rate of more than 90%. However, due to the lack of awareness and understanding of apical microsurgery by dental general practitioners and even endodontists, many clinical problems remain to be overcome. The consensus has gathered well-known domestic experts to hold a series of special discussions and reached the consensus. This document specifies the indications, contraindications, preoperative preparations, operational procedures, complication prevention measures, and efficacy evaluation of apical microsurgery and is applicable to dentists who perform apical microsurgery after systematic training.
Microsurgery/standards* ; Humans ; Apicoectomy ; Contraindications, Procedure ; Tooth Apex/diagnostic imaging* ; Postoperative Complications/prevention & control* ; Consensus ; Treatment Outcome